The American Academy of Neurology reports:
“The AAN opposes generic substitution of anticonvulsant drugs for the treatment of epilepsy without the attending physician’s approval.
The FDA has allowed for significant differences between name-brand and generic drugs.
This variation can be highly problematic for patients with epilepsy.
Even minor differences in the composition of generic and name-brand anticonvulsant drugs for the treatment of epilepsy can result in breakthrough seizures.”
Please read this article. It’s from those who know best and truly have OUR interests at heart!
To subscribe to Epilepsy Talk and get the latest articles, simply go to the bottom box of the right column, enter your email address and click on “Follow”
Resource:
The New York Times
http://graphics8.nytimes.com/package…angenerics.pdf
Thanks for info about *New Meds many of us are waiting for. Have A Blessed Holiday ans 2026, Phylis.Effie Jane
LikeLiked by 1 person
Comment by Effie Erhardt — December 22, 2025 @ 10:42 PM
Thank you. Wishing you health, happiness, love and laughter.
LikeLike
Comment by Phylis Feiner Johnson — December 23, 2025 @ 10:10 AM
The article is from 2006. In spite of the hostility of some government interests towards healthcare, things may have improved. I went onto generic lamotrigine XR a few months ago and never notice the faintest effect.
LikeLike
Comment by Jeffrey Lee Hatcher — January 16, 2026 @ 11:13 AM
Jeffrey, The fact still remains that 1/3 of generics are comprised of unknown fillers.
(That being said, I’m on generic lamotrigine XR, too.)
LikeLike
Comment by Phylis Feiner Johnson — January 16, 2026 @ 11:17 AM